Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Amgen's muscular disorder drug meets main goal in late-stage study
Amgen's muscular disorder drug meets main goal in late-stage study
Amgen's muscular disorder drug meets main goal in late-stage study
Submitted by
admin
on September 24, 2024 - 9:59pm
Source:
Reuters
News Tags:
Amgen
Uplinza
clinical trials
myasthenia gravis
Headline:
Amgen's muscular disorder drug meets main goal in late-stage study
snippet:
Amgen's Uplizna succeeds in study for muscle-weakening
Analysts say data from another experimental drug not 'competitive'
Shares fall 2% in extended trading on mixed datasets
Do Not Allow Advertisers to Use My Personal information
